Tpg-backed Sai Life Sciences Picks 4 I-banks; To Soon Kick Off Rs 5,000 Cr-rs 5,500 Cr Ipo
Before switching to the listing route, TPG-backed Sai Life Sciences had explored the sale of a controlling stake in the firm and conducted a sale process, which resulted in Bain Capital emerging as the front-runner in the final leg, according to a January 25 report by Moneycontrol. But talks between both parties did not fructify into a deal.
Goldman Sachs Asset Management Raises $650M For Life Sciences I Fund, Targets Innovation - Goldman Sachs Gr (nyse:gs)
The Goldman Sachs Group Inc's (NYSE: GS) Goldman Sachs Asset Management recently read more. :
The Goldman Sachs Group Inc's GS Goldman Sachs Asset Management recently disclosed the closure of the West Street Life Sciences I fund. The company stated that Life Sciences I closed above its fundraising target with $650 million in equity commitments. The fund represents the first in the firm's Life Sciences Investing strategy and is one of the largest ever first-time private life sciences growth funds. The fund is managed by Goldman Sachs Asset Management's Life Sciences Investing Group, established in 2021 and led by Amit Sinha.
Healthcare & Life Sciences Private Equity Deal Tracker: Gryphon Sells Potter To Kkr | Mcguirewoods Llp
Gryphon Investors has announced it has sold Potter Global Technologies to investment funds managed by KKR. Potter, based in St. Louis, Mo., is global provider of fire safety and emergency communication products....By: McGuireWoods LLP.
Bain, Kkr, Advent Circle Sai Life Sciences
Both TPG and its current promoter Krishna Kanumuri may sell stakes as part of the transaction. :
Mumbai: Global private equity funds, including Bain Capital, KKR, and Advent International, are in talks for a controlling stake in Sai Life Sciences at a valuation of $600-700 million, three people aware of the development said. Sai Life Sciences (SLS) is a Hyderabad-based pharmaceutical contract research and development, and manufacturing (CRDMO) firm.
Healthcare & Life Sciences Private Equity Deal Tracker: Lovell Minnick Acquires S&s Health | Mcguirewoods Llp
Lovell Minnick Partners (LMP) has announced it has completed a majority investment in S&S Health....By: McGuireWoods LLP. :
Lovell Minnick Partners (LMP) has announced it has completed a majority investment in S&S Health. S&S, founded in 1994 and based in Mason, Ohio, is a healthcare administration company providing solutions for health plans for small and mid-sized businesses. LMP, based in Rednor, Pa., is private equity firm which seeks to invest in growth-oriented financial services and financial technology companies. Founded in 1999, the firm generally makes equity investments between $40 million and $150 million.
Preventative Health And Longevity Company, Viome Life Sciences, Closes $86.5M Oversubscribed Series C Funding Round
The additional financing supports the further development of its suite of advanced personalized health tests and expansion into key nationwide retailers such as CVS BELLEVUE, Wash., Aug. 18, 2023 /PRNewswire/ -- Viome Life Sciences, a longevity company committed to translating scientific...
Life Sciences Real Estate Update - 3.21.23 | Allen Matkins
Despite a strong start last year, venture capital funding for life sciences totaled $35.8 billion in 2022, down 28% from 2021, according to Cushman & Wakefield (C&W). Initial public offering activity also fell 90% from $14.5 billion in 2021 to $1.4 billion in 2022....By: Allen Matkins.
Life Sciences Real Estate Update - 2.08.23 | Allen Matkins
Last year’s solid venture capital investment in life sciences was, as expected, focused on the big three markets of San Diego, Boston, and San Francisco. But as a recent Cushman & Wakefield report found, emerging markets saw significant spikes of interest, perhaps suggesting a shift toward building startups and more lab space outside established markets....By: Allen Matkins.
Catalio Capital Management Launches Long-short Public Equities Strategy Focused On Global Healthcare And Life Sciences Sectors | Business Wire
NEW YORK--(BUSINESS WIRE)--Catalio Capital Management, LP (“Catalio”), a leading multi-strategy life sciences investment firm with more than $1 billion in assets under management, today announced the launch of its dedicated public equities hedge fund investment strategy focused on identifying compelling life science investment opportunities globally. In connection with the launch of the vehicle, the seasoned investment team from HealthCor Management (“HealthCor”), a well-established healthcare.
Healthcare & Life Sciences Private Equity Deal Tracker: Viewside Capital And Morningside Invest In Resilience Lab | Mcguirewoods Llp
Viewside Capital Partners and Morningside Group have co-led a $15 million series A funding round in Resilience Lab, according to a news release. Resilience Lab, based in New York, is a mental health technology company....By: McGuireWoods LLP.